Patents by Inventor Rongrong XIE

Rongrong XIE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250171816
    Abstract: The present invention relates to an enzyme combination, genetically engineered bacteria, and application thereof in producing D-psicose. Glucose isomerase and D-psicose 3-epimerase from specific sources are separately co-expressed in Bacillus subtilis, a combination enzyme containing glucose isomerase and D-psicose 3-epimerase is obtained through fermentation, and the combination enzyme is used to catalyze a glucose substrate to perform isomerization to eventually prepare D-psicose. The method provided in the present invention can clearly increase a conversion rate of D-psicose, which greatly reduces the time of converting glucose into D-psicose. In addition, inexpensive glucose is used as a raw material, so that the production costs of D-psicose are greatly reduced. In the present invention, fructose syrup may be synchronously produced, so that the input for a whole set of production lines of fructose syrup is omitted, thereby greatly improving the economic benefits.
    Type: Application
    Filed: January 30, 2025
    Publication date: May 29, 2025
    Inventors: Sanying WANG, Ziheng JIN, Yanjun WEN, Linzheng LI, Chenhui WEN, Rongrong XIE, Tianyi PAN
  • Publication number: 20250171817
    Abstract: The present invention relates to an enzyme combination, genetically engineered bacteria, and application thereof in producing D-psicose. In the present invention, glucose isomerase and D-psicose 3-epimerase from specific sources are co-expressed in Bacillus subtilis. A crude enzyme preparation is obtained by fermenting obtained engineered bacteria, and isomerization is performed by using high-concentration glucose as a substrate. Fructose syrup and D-psicose syrup are obtained by performing isolation, purification, and concentration. The enzyme combination provided in the present invention has a high catalytic rate for a substrate, and can clearly increase a conversion rate of D-psicose. In addition, inexpensive glucose is used as a raw material, so that the production costs of D-psicose are greatly reduced.
    Type: Application
    Filed: January 30, 2025
    Publication date: May 29, 2025
    Inventors: Sanying WANG, Ziheng JIn, Yanjun Wen, Linzheng Li, Chenhui Wen, Rongrong Xie, Tianyi Pan
  • Patent number: 12240841
    Abstract: An FXR small molecule agonist and a preparation method therefor and a use thereof, having a structure as shown in formula (I). The compound represented by formula (I) has FXR agonistic activity and is capable of preparing drugs for treatment of FXR-related diseases.
    Type: Grant
    Filed: April 20, 2020
    Date of Patent: March 4, 2025
    Assignees: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES, VAN ANDEL RESEARCH INSTITUTE
    Inventors: Huaqiang Xu, Jia Li, Jingjing Shi, Yi Zang, Dandan Sun, Mingliang Liu, Rongrong Xie, Erli You, Lixin Gao, Qian Tan
  • Publication number: 20240301344
    Abstract: A method for preserving a fermentation broth of an engineered strain of D-psicose-3-epimerase includes: adding a lysozyme into a fermentation broth of an engineered strain of D-psicose-3-epimerase, stirring to make the OD600 of the fermentation broth less than or equal to 1 to obtain an enzyme solution; and adjusting the enzyme solution to be weakly alkaline with an alkali liquor, and storing the weakly alkaline enzyme solution at room temperature. According to the invention, the enzyme solution is obtained by adding the lysozyme after fermentation, and then adjusted to be weakly alkaline. The lysozyme can dissolve the engineered strain to release the enzyme, and can also inhibit the growth of microorganisms. The alkaline environment of the enzyme solution can further inhibit the growth of other microorganisms in the enzyme solution. Therefore, the storage life of the enzyme solution is prolonged while ensuring the enzyme activity.
    Type: Application
    Filed: September 20, 2023
    Publication date: September 12, 2024
    Inventors: Zhewei ZHAO, Sanying WANG, Ziheng JIN, Yanjun WEN, Linzheng LI, Rongrong XIE, Tianyi PAN
  • Publication number: 20230357244
    Abstract: A strong FXR small-molecule agonist, and a preparation method therefor and use thereof, the structure of the agonist being represented by formula (I), are provided. In the formula, each substituent is as defined in the description and the claims. The compound provided has the advantages of high FXR agonist activity, simple synthesis, easily available raw materials and the like, and can be used for preparing medicines for treating FXR related diseases.
    Type: Application
    Filed: September 28, 2021
    Publication date: November 9, 2023
    Inventors: Huaqiang XU, Jia LI, Jingjing SHI, Yi ZANG, Dandan SUN, Mingliang LIU, Rongrong XIE, Erli YOU, Lixin GAO, Qian TAN
  • Publication number: 20220259306
    Abstract: Provided are an antibody targeting NKG2A, a preparation method therefor and use thereof. Specifically, provided is a new mouse or humanized monoclonal antibody targeting NKG2A, and a method for preparing the monoclonal antibody. The monoclonal antibody can bind to an NKG2A antigen with high specificity, and has high affinity and significant activities such as anti-tumor activity.
    Type: Application
    Filed: November 6, 2019
    Publication date: August 18, 2022
    Inventors: Qing DUAN, Lile LIU, Dazhi YANG, Jing GAO, Lili HU, Ruirui SUI, Dongxu WANG, Ye HAN, Rongrong XIE, Yan LU, Xiaohui SHAO, Jie ZHANG, Wenming ZHOU, Cuicui GUO, Guozhen TONG, Lina WANG, Chaohui DAI, Mengying WANG
  • Publication number: 20220213083
    Abstract: An FXR small molecule agonist and a preparation method therefor and a use thereof, having a structure as shown in formula (I). The compound represented by formula (I) has FXR agonistic activity and is capable of preparing drugs for treatment of FXR-related diseases.
    Type: Application
    Filed: April 20, 2020
    Publication date: July 7, 2022
    Inventors: Huaqiang XU, Jia LI, Jingjing SHI, Yi ZANG, Dandan SUN, Mingliang LIU, Rongrong XIE, Erli YOU, Lixin GAO, Qian TAN
  • Publication number: 20220098319
    Abstract: An antibody targeting CD73, a preparation method therefor and a use thereof. The provided monoclonal antibody can bind to a CD73 antigen with high specificity, and has high affinity and significant antitumor activity.
    Type: Application
    Filed: January 13, 2020
    Publication date: March 31, 2022
    Inventors: Dongxu WANG, Qing DUAN, Lile LIU, Tatchi Teddy YANG, Hu LIU, Ye HAN, Rongrong XIE, Xiaohui SHAO, Peng WANG, Qin ZHONG, Yajun HUANG, Jian WU, Meiling WANG, Yuandong WANG